Search clinical trials for: Recurrent ovarian carcinosarcoma

Total 16444 results

National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma | Ovarian... and other conditions

United States, Canada, Singapore
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Endometrial Adenosquamous... and other conditions

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (P204)

Ovarian Cancer | Carcinosarcoma | Endometrial Cancer | Uterine Cancer

United States
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Ohio State University Comprehensive Cancer Center
ImmunoGen, Inc.; Clovis Oncology, Inc.

Active, not recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...

United States
Vanderbilt-Ingram Cancer Center
AstraZeneca; Syndax Pharmaceuticals

Terminated

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Primary Peritoneal... and other conditions

United States
Imperial College London
North Eastern German Society of Gynaecological Oncology; Takeda Pharmaceuticals...

Active, not recruiting

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (DICE)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma

United Kingdom, Germany
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Mixed Mesodermal (Mullerian) Tumor | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage... and other conditions

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Cancer
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Sarcoma | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute

Completed

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Desmoid Tumor | Adult Malignant Fibrous Histiocytoma of Bone

United States
National Cancer Institute (NCI)

Completed

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditions

United States, Canada
University of South Florida
National Cancer Institute (NCI)

Terminated

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Cancer

United States
National Cancer Institute (NCI)

Completed

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Cervical Cancer | Head and Neck Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Malignant Mesothelioma | Primary Peritoneal Cavity Cancer

United States
National Cancer Institute (NCI)

Completed

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Cervical Cancer | Head and Neck Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Malignant Mesothelioma | Primary Peritoneal Cavity Cancer

United States
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Completed

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Sarcoma | Kidney Cancer | Ovarian Cancer | Endometrial Cancer | Pheochromocytoma

France, Canada, Switzerland, Denmark, Belgium, Netherlands, United Kingdom, Germany, Italy, Slovakia, Spain, Portugal, Austria
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Uterine Carcinosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Adult Angiosarcoma | Adult Epithelioid Sarcoma | Adult Leiomyosarcoma | Adult Synovial Sarcoma and other conditions

United States
Herbert Irving Comprehensive Cancer Center

Unknown

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Sarcoma | Ovarian Cancer | Endometrial Cancer

United States
European Organisation for Research and Treatment...

Completed

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Endometrial Cancer | Melanoma (Skin)

Belgium
European Organisation for Research and Treatment...

Completed

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal Tumor

France, Denmark, Netherlands, Belgium, United Kingdom
European Organisation for Research and Treatment...

Completed

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Ovarian Cancer

China
PhotonPharma, Inc.

Not yet recruiting

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer

Ovarian Cancer
ImmunoGen, Inc.

Not yet recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian Cancer | Folate Receptor-Alpha Positive

United States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Not yet recruiting

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Gynecologic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Dana-Farber Cancer Institute
ImmunityBio, Inc.

Not yet recruiting

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Recurrent Ovary Cancer | Ovarian Carcinoma, Recurrent

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

China
Assiut University

Not yet recruiting

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

Ovarian Cancer
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
Valerio Therapeutics

Recruiting

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Breast Cancer | Prostate Cancer | Advanced or Metastatic Solid Tumors | Recurrent Ovarian Cancer

United States
Fengzhi Feng

Recruiting

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Recurrent Ovarian Carcinoma

China
Peking Union Medical College Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Second Affiliated...

Recruiting

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma

China
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Chang Gung Memorial Hospital

Recruiting

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Ovarian Cancer

Taiwan

Search clinical trials for: Recurrent ovarian carcinosarcoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations